Cognition Therapeutics (CGTX) Competitors $0.84 -0.02 (-2.51%) Closing price 04:00 PM EasternExtended Trading$0.84 +0.00 (+0.12%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. ENTA, ACOG, ALEC, GLSI, IMRX, MOLN, THTX, TNYA, LIMN, and IKTShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Enanta Pharmaceuticals (ENTA), Alpha Cognition (ACOG), Alector (ALEC), Greenwich LifeSciences (GLSI), Immuneering (IMRX), Molecular Partners (MOLN), Theratechnologies (THTX), Tenaya Therapeutics (TNYA), Liminatus Pharma (LIMN), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Its Competitors Enanta Pharmaceuticals Alpha Cognition Alector Greenwich LifeSciences Immuneering Molecular Partners Theratechnologies Tenaya Therapeutics Liminatus Pharma Inhibikase Therapeutics Cognition Therapeutics (NASDAQ:CGTX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has more risk and volatility, CGTX or ENTA? Cognition Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Which has higher earnings & valuation, CGTX or ENTA? Cognition Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$33.97M-$0.74-1.14Enanta Pharmaceuticals$64.46M2.45-$116.04M-$4.54-1.63 Is CGTX or ENTA more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -149.57%. Enanta Pharmaceuticals' return on equity of -79.83% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -194.42% -115.14% Enanta Pharmaceuticals -149.57%-79.83%-26.65% Do insiders & institutionals believe in CGTX or ENTA? 43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to CGTX or ENTA? In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 2 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 1.45 beat Cognition Therapeutics' score of 0.93 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CGTX or ENTA? Cognition Therapeutics currently has a consensus price target of $2.83, suggesting a potential upside of 237.30%. Enanta Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 143.24%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 SummaryCognition Therapeutics beats Enanta Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.07M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-1.1421.1828.1120.03Price / SalesN/A337.65460.63103.88Price / CashN/A43.2336.5559.01Price / Book2.718.368.655.90Net Income-$33.97M-$55.19M$3.25B$258.66M7 Day Performance28.44%5.89%4.20%2.23%1 Month Performance180.00%17.63%10.83%12.77%1 Year Performance-60.00%5.10%34.67%19.36% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics2.7831 of 5 stars$0.84-2.5%$2.83+237.3%-53.2%$52.07MN/A-1.1420ENTAEnanta Pharmaceuticals3.9217 of 5 stars$7.73+2.5%$18.00+132.9%-51.1%$161.18M$67.64M-1.70160Positive NewsACOGAlpha Cognition1.7311 of 5 stars$9.98-0.1%$20.00+100.4%N/A$160.04MN/A-8.32N/APositive NewsALECAlector4.0601 of 5 stars$1.62+1.9%$4.00+146.9%-71.7%$158.99M$100.56M-1.29270Positive NewsGLSIGreenwich LifeSciences2.2011 of 5 stars$11.76+1.5%$39.00+231.6%-26.1%$154.94MN/A-9.333High Trading VolumeIMRXImmuneering3.1256 of 5 stars$4.24+2.7%$13.25+212.5%+247.8%$148.62M$320K-2.1660MOLNMolecular Partners2.6099 of 5 stars$3.79+5.4%$12.00+216.3%-38.4%$145.15M$5.65M-1.98180News CoverageGap UpTHTXTheratechnologiesN/A$3.14flatN/A+117.2%$144.38M$85.87M-16.53140Positive NewsTNYATenaya Therapeutics3.8258 of 5 stars$0.86-2.3%$6.25+629.6%-77.2%$142.68MN/A-0.74110Positive NewsLIMNLiminatus PharmaN/A$5.58+3.0%N/AN/A$141MN/A0.00N/ANews CoverageGap DownIKTInhibikase Therapeutics1.2218 of 5 stars$1.88+2.2%$6.50+245.7%+12.8%$139.76MN/A-0.706News Coverage Related Companies and Tools Related Companies Enanta Pharmaceuticals Competitors Alpha Cognition Competitors Alector Competitors Greenwich LifeSciences Competitors Immuneering Competitors Molecular Partners Competitors Theratechnologies Competitors Tenaya Therapeutics Competitors Liminatus Pharma Competitors Inhibikase Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGTX Stock Alerts